Poai reports strong results from its ai cancer drug evaluation

Minneapolis, jan. 13, 2022 (globe newswire) -- predictive oncology inc. (nasdaq: poai) reported the preliminary results of its discovery 2021 program today, announcing that its helomics subsidiary's evaluation demonstrated their proprietary artificial intelligence (ai) program core™ (computational research engine), combined with their tumor profile data and matched ovarian cancer samples, could identify potential new chemotherapy drug uses. these drugs are not currently approved for ovarian cancer, but, with further study, could be used for ovarian cancer treatment following clinical trial and regulatory approval.
POAI Ratings Summary
POAI Quant Ranking